Weixuan (Agnes) Yu Ph.D., Bcmas Email & Phone Number

United States

Greater Philadelphia

Greater Philadelphia Area

Singapore

Singapore

Lead a team of 4 people for outreach and marketing implementation at Biotech Connection SingaporeIncrease visibility of Biotech Connection Singapore within the Life Sciences eco-system in Singapore by networking and relationship-building with: Singapore-based life science companies (startups, SMEs, MNCs) Local tertiary and research institutions Other players in the life science eco-system in Singapore (NRF, local incubators and accelerators, potential investors)Take the lead in generating marketing collaterals for Biotech Connection Singapore

Singapore

Developed medium-to-high throughput screening biochemical assay for proof-of-concept studies and compound screeningConducted follow-up mechanistic studies and supported lead optimizationMaintained broad knowledge of literature and state-of-the-art technologyWritten and verbal communications of study plans and results to project leader as well as at departmental levelsInterface broadly with medical chemists and preclinical pharmacology teams

Greater New York City Area

Explored the time-dependent inhibition mechanism of the enoyl-ACP reductase from Mycobacterium tuberculosis (InhA), provided mechanistic insight for future drug design on InhADesigned novel scaffold InhA inhibitors based on the mechanism. Successfully increased the drug-target lifetime (residence time) from 1 h (Isoniazid) to 10 h, could potentially improve drug efficacy, target occupancy and selectivityBuilt computational enzyme kinetic model on InhA, able to obtain insightful kinetic parameters by solving the model numericallyInvestigating the post antibiotic effect (PAE) of InhA inhibitors, addressing the concept of target vulnerability

New York Stock Exchange

Conducted industry research and investment analyses for molecular diagnostics and personalized medicine in the US and China marketDissected the industrial landscape analysis into 7 different sectors, including general investment landscape, market analysis, technology trend, regulatory framework, reimbursement strategy, intellectual property landscape and business models adopted by current major playersPerformed fundamental company analysis on small-mid cap stocks in the molecular diagnostic sector, including Myriad Genetics (MYGN), Genomic Health (GHDX), Sequenom (SQNM), NeoGenomics (NEO), Foundation Medicine (FMI), Transgenomic (TBIO), Veracyte (VCYT), Response Genetics (RGDX), Cancer genetics (CGIX), CombiMatrix (CBMX), Interlukin Genetics (ILIU) and MDx Health (MDXH); identified potential development pathways and investment return for prospective portfolio companiesEvaluated 2 startup business plans for scientific merit and commercial value; analyzed risks and opportunities based on the above industrial and company analysis; evaluated track record of management teams, prioritized project portfolio and identified potential partnership opportunities to pursue specific investmentProduced comprehensive report to highlight industry trend and delivered presentations to both internal and external clients

Greater New York City Area

Evaluated and analyzed a novel drug-conjugate (ADC) technology for cancer treatmentConducted due diligence on market size, competitive landscape, intellectual property, FDA regulatory affairs and exit opportunitiesFormulated financial analysis and final recommendation to Technology of Licensing and Industry relations at Stony Brook University

Identified 4 novel drug candidates with better efficacy than standard therapy, resulting in provisional patent applicationFacilitated and advanced the collaboration by hosting tele-conference meetings

Conducted due diligence, compiled and prepared 3 analysis reports in the China oil/gas market sector based on the information obtained through primary and secondary researchFormulated market entry strategy for a multinational chemical vendor by collaborating with colleagues from Beijing, Shanghai and Hong KongProduced summaries of qualitative and quantitative information for senior analystHelped on preparing deliverables for briefings and conferences

Doctor Of Philosophy (Ph.D.), Chemical Biology

Certificate In Marketing, Marketing/Marketing Management, General, 90/100

Branding; Customer Centricities; Market Strategy

Bachelor Of Engineering (Beng), Materials Science